Bowel Cancer: A New Treatment Option | FT Doug Cockle | Stand Up To Cancer (2019)

Bowel Cancer: A New Treatment Option | FT Doug Cockle | Stand Up To Cancer (2019)


Bowel cancer is the 4th most common cancer in the UK Stand Up To Cancer is supporting research into an entirely new treatment option for people with bowel cancer, by investigating a molecule called GREMLIN1 Despite its scary name, GREMLIN1 plays an important role in maintaining our gut, from ensuring it develops correctly in the womb, helping it repair when its injured and keeping it healthy as an adult We clearly do need this little fella but importantly, it must be controlled Normally, GREMLIN1 is produced by healthy ‘stromal cells’ which surround the gut lining and support its function And because bowel cancer originates from the bowel lining, bowel tumours are also surrounded by stromal cells It’s thought that bowel cancer cells can hijack their surrounding stromal cells and cause them to make way too much GREMLIN1, providing an environment in which bowel cancer cells can thrive Scientists hope to use this as an Achilles’ heel Most bowel cancer treatments only target the tumour cells themselves, but this one aims to develop a drug that targets the surrounding stromal cells, bringing the production of GREMLIN1 back under control and ultimately, providing a new way to treat bowel cancer Across the UK, Stand Up To Cancer is funding cutting edge research like this, to help bring new treatments to patients faster – ultimately saving more lives

One thought on “Bowel Cancer: A New Treatment Option | FT Doug Cockle | Stand Up To Cancer (2019)

Leave a Reply

Your email address will not be published. Required fields are marked *